ARROWHEAD PHARMACEUTICALS, INC.

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

ARWR

Insider Sentiment (TTM):

Last Purchase:2024-04-18Last Sale:2026-05-12Shares Purchased (TTM):0Shares Sold (TTM):453,456

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:117,932,807Shares Outstanding:142,417,000Institutional Ownership Pct.:82.81%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Consolidated Entity Excluding Variable Interest En…	-	76	71	89	-	-	-	76	-	-	-	-
Variable Interest Entity Primary Beneficiary	-	-89	130	138	-	-	-	26	-	-	-	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	55	189	202	227	130	186	54	103	69	128	58	111
Available For Sale Securities Debt Securities Curr…	-	-	714	693	771	912	499	578	367	395	162	293
Accounts Receivable Net Current	9	16	219	7	10	2	3	0	-	-	-	0
Short Term Investments	-	1,596	715	-	-	-	-	-	-	-	-	-
Prepaid Expense Current	25	22	16	11	24	24	9	10	9	11	11	9
Other Assets Current	36	18	23	14	13	12	6	5	4	8	7	4
Held To Maturity Securities Current	-	-	-	-	-	-	-	-	-	-	-	0
Assets Current	1,671	1,840	1,174	951	947	1,135	571	695	450	542	238	416
Property Plant And Equipment Net	373	375	379	383	381	385	387	386	376	359	333	290
Finite Lived Intangible Assets Net	6	6	6	7	7	8	8	9	9	9	10	10
Operating Lease Right Of Use Asset	56	43	43	44	44	44	45	45	44	45	45	45
Other Assets Noncurrent	6	5	1	1	1	1	3	4	4	0	0	3
Held To Maturity Securities Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Assets	2,112	2,268	1,604	1,385	1,381	1,573	1,014	1,140	884	955	626	766
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	28	31	33	18	33	10	14	11	27	9	4	36
Accrued Liabilities Current	86	77	130	90	65	78	59	63	48	37	47	40
Employee Related Liabilities Current	23	20	14	27	19	17	11	22	16	14	9	18
Operating Lease Liability Current	5	8	8	7	7	7	7	6	6	5	3	11
Contract With Customer Liability Current	95	109	112	2	23	43	0	0	0	0	0	1
Lines Of Credit Current	40	40	40	40	40	65	2	0	-	-	-	-
Other Liabilities Current	6	11	11	11	7	0	0	0	0	1	0	0
Liabilities Current	283	295	347	195	195	221	94	103	97	65	64	105
Liabilities Noncurrent
Operating Lease Liability Noncurrent	114	100	102	104	106	108	109	111	112	114	115	105
Contract With Customer Liability Noncurrent	32	49	54	-	0	0	0	-	-	-	-	0
Long Term Line Of Credit	141	160	163	215	200	209	408	393	-	-	-	0
Convertible Debt Noncurrent	683	682	-	-	-	-	-	-	-	-	-	-
Liabilities Noncurrent	1,363	1,374	694	686	666	669	864	846	448	395	389	373
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,443	2,395	2,211	2,140	2,120	2,107	1,847	1,806	1,786	1,769	1,320	1,300
Accumulated Other Comprehensive Income Loss Net Of…	-1	1	7	6	5	4	4	5	-1	-1	-1	-3
Retained Earnings Accumulated Deficit	-1,923	-1,729	-1,596	-1,627	-1,603	-1,428	-1,799	-1,626	-1,455	-1,284	-1,159	-1,026
Treasury Stock Common Value	-53	-53	-53	-53	-	-	-	0	-	-	-	-
Stockholders Equity	466	599	568	466	522	684	56	191	331	495	174	271
Minority Interest	1	-15	-6	37	-3	1	3	6	8	12	13	16
Liabilities And Stockholders Equity	2,112	2,268	1,604	1,385	1,381	1,573	1,014	1,140	884	955	626	766
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	290	290	290	290	290	290	290	290	290	290	290	290
Common Stock Shares Issued	144	143	140	136	138	138	126	124	124	124	108	107
Shares Outstanding	141	141	137	136	138	138	126	124	124	124	108	107
Treasury Stock Common Shares	3	3	3	3	-	-	-	0	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.12%	-10.61%	14.34%	-0.05%	1.21%	9.81%	-	-	-	-	-	-
2025	-14.81%	-46.39%	-27.61%	20.33%	20.19%	14.03%	37.17%	104.23%	136.61%	45.67%	36.44%	36.40%
2024	8.67%	-13.86%	-33.37%	-7.16%	5.14%	14.04%	-7.81%	-23.91%	-22.24%	-7.60%	-7.08%	-5.23%
2023	-	-	-	-	-	-	-9.25%	-12.79%	-23.40%	4.73%	16.46%	1.73%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.90	6.23	3.38	4.86	4.87	5.15	6.09	6.74	4.65	8.31	3.73	3.95
Quick Ratio	5.81	6.16	3.33	4.81	4.75	5.04	5.99	6.65	4.56	8.14	3.57	3.87
Working Capital	1.39B	1.54B	826.96M	755.15M	752.39M	914.68M	476.78M	592.30M	353.35M	476.48M	174.18M	311.02M
Leverage & Debt
Debt to Equity	3.54	2.79	1.83	1.75	1.65	1.30	17.08	4.97	1.65	0.93	2.61	1.67
Interest Coverage TTM	-2.45	-2.40	3.33	1.10	-1.31	-1.88	-12.87	-18.58	-23.83	-20.57	-14.36	-11.19
Debt Ratio	0.78	0.74	0.65	0.64	0.62	0.57	0.94	0.83	0.62	0.48	0.72	0.62
Efficiency & Turnover
Asset Turnover TTM	0.38	0.32	0.83	0.66	0.51	0.43	0.00	0.00	0.02	0.04	0.24	0.33
Days Sales Outstanding TTM	4.98	5.30	37.03	3.00	6.18	1.58	365.00	-	-	-	-	-
Receivables Turnover TTM	73.35	68.92	9.86	121.55	59.08	230.53	1.00	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.97	-1.87	1.66	0.23	-1.08	-1.06	-5.10	-5.00	-4.39	-3.87	-2.82	-1.96
Free Cash Flow Per Share TTM	-0.52	-0.36	2.35	1.17	-0.13	0.07	-4.58	-5.05	-4.29	-3.81	-3.75	-3.10
Dividend Per Share TTM	0.31	0.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	111.47%	107.61%
Operating Profit Margin TTM	-33.82%	-35.67%	27.55%	11.86%	-18.84%	-21.74%	-25,037.88%	-16,927.06%	-2,785.05%	-1,335.58%	-164.75%	-85.16%
Net Profit Margin TTM	-42.15%	-42.86%	21.45%	3.63%	-26.21%	-26.11%	-25,488.08%	-16,882.37%	-2,775.65%	-1,346.13%	-166.63%	-86.93%
Growth Metrics
Net Revenue Growth (1Y)	16.85%	14.09%	43,539.24%	23,258.15%	2,816.21%	1,436.97%	-98.62%	-98.52%	-92.33%	-87.00%	-34.71%	-1.03%
Net Income Growth (1Y)	87.89%	87.28%	-136.72%	-105.02%	-72.46%	-70.19%	110.41%	186.46%	197.97%	213.90%	94.84%	18.57%
EPS Growth (1Y)	82.20%	75.38%	-133.46%	-104.50%	-75.40%	-72.44%	81.03%	155.29%	156.72%	171.82%	92.34%	17.10%
Valuation Metrics
P/E TTM	-41.41	-33.50	38.88	153.19	-14.63	-11.94	-3.68	-3.87	-5.92	-7.38	-10.85	-13.71
P/B TTM	25.10	14.91	16.01	9.16	4.21	2.48	41.86	12.14	9.77	7.12	18.92	9.99
P/S TTM	17.46	14.36	8.34	5.56	3.83	3.12	938.86	653.40	164.29	99.40	18.09	11.92
Market Cap	11.69B	8.93B	9.10B	4.61B	2.20B	1.70B	2.35B	2.32B	3.23B	3.53B	3.29B	2.87B
Enterprise Value	12.35B	9.46B	8.94B	4.43B	2.11B	1.58B	2.29B	2.22B	3.16B	3.40B	3.23B	2.76B
Calculated Values
Free Cash Flow TTM	-75.11M	-50.87M	322.01M	156.89M	-17.62M	9.60M	-571.61M	-604.32M	-532.65M	-470.16M	-402.70M	-330.63M
Net Debt	667.95M	533.42M	-161.64M	-186.55M	-89.79M	-120.71M	-52.26M	-102.69M	-69.40M	-127.70M	-58.22M	-110.89M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-12Sale

Owner: Lu, Hongbo

Title: -

Shares: 2,970

Price/Share: $76.88

Value: $228,333.60

Shares Owned: 52,012

Relationship: Director

Ownership: Direct

2026-04-23Sale

Owner: Hamilton, James C

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $75.00

Value: $750,000.00

Shares Owned: 226,958

Relationship: Officer

Ownership: Direct

2026-04-22Sale

Owner: Apel, Daniel Joseph

Title: Chief Financial Officer

Shares: 13,095

Price/Share: $70.83

Value: $927,518.85

Shares Owned: 162,905

Relationship: Officer

Ownership: Direct

2026-03-05Sale

Owner: Hamilton, James C

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $64.19

Value: $641,900.00

Shares Owned: 236,958

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: O'Brien, Patrick

Title: COO

Shares: 49,493

Price/Share: $63.92

Value: $3,163,592.56

Shares Owned: 474,908

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-12	Lu, Hongbo	Director	-	Direct	Sale	2,970	76.88	$228,333.60	52,012	4
2026-04-23	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	10,000	75.00	$750,000.00	226,958	4
2026-04-22	Apel, Daniel Joseph	Officer	Chief Financial Officer	Direct	Sale	13,095	70.83	$927,518.85	162,905	4
2026-03-05	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	10,000	64.19	$641,900.00	236,958	4
2026-01-05	O'Brien, Patrick	Officer	COO	Direct	Sale	49,493	63.92	$3,163,592.56	474,908	4
2026-01-05	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	40,164	64.13	$2,575,717.32	171,958	4
2026-01-02	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	13,187	66.13	$872,056.31	3,792,739	4
2025-12-29	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	51,726	69.01	$3,569,611.26	3,805,926	4
2025-12-26	Ferrari, Mauro	Director	-	Direct	Sale	7,530	70.00	$527,100.00	69,053	4
2025-12-22	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	12,586	68.59	$863,273.74	3,805,926	4
2025-12-19	Olukotun, Adeoye Y	Director	-	Direct	Sale	10,000	67.74	$677,400.00	33,600	4
2025-12-19	Waddill, William D.	Director	-	Direct	Sale	8,367	67.73	$566,696.91	56,563	4
2025-12-19	Vakiener, Victoria	Director	-	Direct	Sale	10,040	67.66	$679,306.40	35,723	4
2025-12-17	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	85,000	64.97	$5,522,450.00	3,831,957	4
2025-12-16	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	54,298	64.05	$3,477,786.90	3,916,957	4
2025-12-05	Perry, Michael S	Director	-	Direct	Sale	16,250	61.03	$991,737.50	115,240	4
2025-11-28	Ferrari, Mauro	Director	-	Direct	Sale	8,750	56.39	$493,412.50	68,764	4
2025-10-01	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	20,000	35.00	$700,000.00	212,122	4
2025-09-12	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	15,000	30.00	$450,000.00	232,122	4
2025-09-02	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	15,000	25.00	$375,000.00	247,122	4
2025-08-15	Hamilton, James C	Officer	Chief Medical Officer	Direct	Sale	9,389	20.00	$187,780.00	262,122	4
2025-04-11	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	50,800	11.49	$583,692.00	3,921,255	4
2025-03-13	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	51,425	15.07	$774,974.75	4,062,377	4
2025-03-04	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	133,333	17.02	$2,269,327.66	3,773,802	4
2025-01-23	Olukotun, Adeoye Y	Director	-	Direct	Sale	959	21.00	$20,139.00	35,781	4
2025-01-07	O'Brien, Patrick	Officer	COO and General Counsel	Direct	Sale	8,000	19.69	$157,520.00	527,201	4
2025-01-07	Myszkowski, Kenneth Allen	Officer	Chief Financial Officer	Direct	Sale	18,000	19.70	$354,600.00	455,433	4
2025-01-06	Hamilton, James C	Officer	Chief Discovery/Trans Medicine	Direct	Sale	32,729	19.90	$651,307.10	272,122	4
2025-01-02	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	11,520	19.05	$219,456.00	3,764,252	4
2024-12-27	Olukotun, Adeoye Y	Director	-	Direct	Sale	2,850	20.00	$57,000.00	36,740	4
2024-12-23	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	12,563	19.59	$246,109.17	3,775,772	4
2024-12-18	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	26,712	21.46	$573,239.52	3,688,335	4
2024-12-17	Waddill, William D.	Director	-	Direct	Sale	3,747	22.04	$82,583.88	40,378	4
2024-12-17	Given, Douglas B	Director	-	Direct	Sale	547	22.04	$12,055.88	124,167	4
2024-12-16	Vakiener, Victoria	Director	-	Direct	Sale	8,994	21.91	$197,058.54	21,211	4
2024-07-02	Oliver, Tracie	Officer	Chief Commercial Officer	Direct	Sale	9,394	25.28	$237,480.32	127,107	4
2024-05-02	Vakiener, Victoria	Director	-	Direct	Sale	1,799	23.31	$41,934.69	30,205	4
2024-04-18	Lu, Hongbo	Director	-	Direct	Purchase	500	22.00	$11,000.00	36,080	5
2024-04-01	Hamilton, James C	Officer	Chief Discovery/Trans Medicine	Direct	Sale	6,000	28.03	$168,180.00	204,851	4
2024-03-20	Lu, Hongbo	Director	-	Direct	Purchase	1,000	27.50	$27,500.00	33,680	4
2024-03-06	Myszkowski, Kenneth Allen	Officer	Chief Financial Officer	Direct	Sale	40,000	35.19	$1,407,600.00	400,600	4
2024-01-31	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	57,499	32.44	$1,865,267.56	3,715,048	4
2024-01-12	Hamilton, James C	Officer	Chief Discovery/Trans Medicine	Direct	Sale	7,940	36.92	$293,144.80	210,851	4
2024-01-11	Given, Douglas B	Director	-	Direct	Sale	2,911	38.16	$111,083.76	129,711	4
2024-01-11	Vakiener, Victoria	Director	-	Direct	Sale	4,720	38.36	$181,059.20	32,001	4
2024-01-11	Ferrari, Mauro	Director	-	Direct	Sale	3,147	38.22	$120,278.34	60,778	4
2024-01-11	Waddill, William D.	Director	-	Direct	Sale	3,934	38.20	$150,278.80	47,870	4
2024-01-05	Myszkowski, Kenneth Allen	Officer	Chief Financial Officer	Direct	Sale	16,104	34.89	$561,868.56	440,600	4
2024-01-05	O'Brien, Patrick	Officer	COO and General Counsel	Direct	Sale	22,841	34.88	$796,694.08	464,385	4
2024-01-05	Oliver, Tracie	Officer	Chief Commercial Officer	Direct	Sale	74	33.89	$2,507.86	136,501	4
2024-01-05	San, Martin Javier	Officer	Chief Medical Officer	Direct	Sale	8,303	34.93	$290,023.79	198,497	4
2024-01-05	Hamilton, James C	Other	-	Direct	Sale	32,143	34.90	$1,121,790.70	218,791	4
2024-01-02	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	9,952	30.99	$308,412.48	3,715,048	4
2023-12-20	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	12,000	28.54	$342,480.00	3,725,000	4
2023-11-20	San, Martin Javier	Officer	Chief Medical Officer	Direct	Sale	19,700	28.86	$568,542.00	131,800	4
2023-10-25	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	24,338	24.21	$589,222.98	3,737,000	4
2023-09-28	Vakiener, Victoria	Director	-	Direct	Sale	1,550	26.33	$40,811.50	21,734	4
2023-09-18	Anzalone, Christopher Ric…	Director,Officer	Chief Executive Officer	Direct	Sale	57,755	28.14	$1,625,225.70	3,761,338	4
2023-07-03	Oliver, Tracie	Officer	Chief Commercial Officer	Direct	Sale	8,925	35.31	$315,141.75	61,575	4
2023-06-30	Hamilton, James C	Other	-	Direct	Sale	3,000	35.53	$106,590.00	188,484	4
2023-06-27	Myszkowski, Kenneth Allen	Officer	Chief Financial Officer	Direct	Sale	15,000	36.20	$543,000.00	381,704	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

82.81%

Inst. Shares: 117,932,807

Shares Outstanding: 142,417,000

2025-12-31

83.85%

Inst. Shares: 114,913,940

Shares Outstanding: 137,039,000

2025-09-30

82.21%

Inst. Shares: 109,966,683

Shares Outstanding: 133,758,000

2025-06-30

74.44%

Inst. Shares: 103,507,520

Shares Outstanding: 139,039,000

2025-03-31

74.54%

Inst. Shares: 99,405,625

Shares Outstanding: 133,363,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	117,932,807	142,417,000	82.81%
2025-12-31	114,913,940	137,039,000	83.85%
2025-09-30	109,966,683	133,758,000	82.21%
2025-06-30	103,507,520	139,039,000	74.44%
2025-03-31	99,405,625	133,363,000	74.54%
2024-12-31	96,049,986	124,848,000	76.93%
2024-09-30	90,723,320	119,784,000	75.74%
2024-06-30	94,156,906	124,199,000	75.81%
2024-03-31	91,876,424	123,285,000	74.52%
2023-12-31	75,081,835	107,415,000	69.90%
2023-09-30	71,249,968	106,750,000	66.74%
2023-06-30	68,516,177	107,004,000	64.03%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — SEC Financial Statements & Analysis

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is a pharmaceutical preparations company, incorporated in DE. ARROWHEAD PHARMACEUTICALS, INC. trades on Nasdaq as: ARWR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ARROWHEAD PHARMACEUTICALS, INC. reported a 16.85% year-over-year revenue growth, a Gross Profit Margin of 111.47% (TTM), a Debt-to-Equity ratio of 3.54x, a Price-to-Sales (P/S) ratio of 17.46x (TTM), a Price-to-Book (P/B) ratio of 25.10x (TTM), at a market cap of $11.69B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 16.85%
Gross Profit Margin TTM: 111.47%
Debt To Equity: 3.54x
P/S TTM: 17.46x
P/B TTM: 25.10x
Market Cap: $11.69B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ARROWHEAD PHARMACEUTICALS, INC. in?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) operates in the Pharmaceutical Preparations industry.

What is ARWR's market cap?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has a market capitalization of $11.69B as of 2026-06-30.

What exchange does ARWR trade on?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) trades on the Nasdaq.

Where is ARROWHEAD PHARMACEUTICALS, INC. incorporated?

ARROWHEAD PHARMACEUTICALS, INC. is incorporated in DE.